EMILY WYATT: Open Payments
NPI 1912197674 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$762 in 36 payments from 12 companies in 2025. Trend: 2023 $1,053 · 2024 $883 · 2025 $762
Food & beverage: $762
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 9 | $195 |
| Axsome Therapeutics, Inc. | 5 | $110 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| Alkermes, Inc. | 3 | $68 |
| ABBVIE INC. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $53 |
| Janssen Pharmaceuticals, Inc | 2 | $43 |
| Lundbeck LLC | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
Products named: FANAPT, REXULTI, Auvelity, ARISTADA, VRAYLAR, CAPLYTA, SPRAVATO, COBENFY.
Industry payments across LA — which companies pay providers there.
